 |
| |
| Oct-09-17 | Initiated |
Piper Jaffray |
Overweight |
$6 |
|
|
|
| Aug-15-18 06:30AM | Altimmune, Inc. to Host Earnings Call ACCESSWIRE |
| Aug-14-18 04:01PM | Altimmune Announces Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire +9.39% |
| Aug-07-18 08:00AM | Altimmune to Announce Second Quarter 2018 Financial Results on August 15 GlobeNewswire |
| Jul-12-18 08:00AM | Altimmune Restructures Financing Agreement with Majority of the Remaining Series B Investors GlobeNewswire |
| Jul-10-18 08:00AM | Altimmune Appoints Mitchel Sayare as Executive Chairman of the Board, and Adds José Ochoa to Its Leadership Team as Chief Business Officer GlobeNewswire |
| Jun-22-18 04:15PM | Altimmune Restructures Financing Agreement GlobeNewswire |
| Jun-11-18 07:10AM | Stock Performance Review on Alder Biopharma and Three Other Biotech Stocks ACCESSWIRE -14.92% |
| Jun-05-18 06:45AM | U.S. hedge fund Hudson Bay to open London office - sources Reuters +5.62% |
| May-24-18 01:47PM | Does Altimmune Incs (NASDAQ:ALT) CEO Salary Reflect Performance? Simply Wall St. -7.77% |
| May-18-18 04:55PM | Gaithersburg biotech faces threat of stock delisting American City Business Journals |
| May-15-18 04:01PM | Altimmune Announces First Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire |
| May-08-18 06:03PM | Who Are The Major Shareholders Of Altimmune Inc (NASDAQ:ALT)? Simply Wall St. |
| 08:00AM | Altimmune to Announce First Quarter 2018 Financial Results on May 16 GlobeNewswire |
| Apr-19-18 07:40AM | Free Research Report as ChemoCentryxs Quarterly Revenues Zoomed More than 1000%; Turned Profitable Y-O-Y ACCESSWIRE |
| Mar-28-18 04:44PM | Altimmune Announces Financial Results for the Year Ended December 31, 2017 and Provides Corporate Update GlobeNewswire -13.04% |
| 11:10AM | Heres Whats Moving Esperion And Altimmune, Inc. Market Exclusive |
| Mar-27-18 08:00AM | Altimmune Announces Positive Data From Its Phase 2a Study of NasoVAX Intranasal Influenza Vaccine and Provides an Update on Its Phase 1b Study of HepTcell Targeted Immunotherapy in Chronic Hepatitis B Infection GlobeNewswire -17.86% |
| Mar-22-18 04:01PM | Altimmune to Participate at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire |
| Mar-20-18 04:01PM | Altimmune to Announce Year End 2017 Financial Results on March 29 GlobeNewswire |
| Mar-12-18 04:34PM | Altimmune Announces Pre-Clinical Data From its SparVax-L Anthrax Vaccine Program GlobeNewswire |
| Mar-06-18 08:00AM | Altimmune to Participate at Two Investor Conferences in March GlobeNewswire -5.73% |
| Jan-23-18 08:00AM | Altimmune Announces Notice of Allowance on Patent Covering Use of NasoShield in the U.S. GlobeNewswire |
| Jan-22-18 08:00AM | Altimmune to Participate at the Noble Capital 14th Annual Investor Conference GlobeNewswire |
| Jan-05-18 12:00PM | Should You Be Concerned About Altimmune Incs (NASDAQ:ALT) Investors? Simply Wall St. |
| Jan-03-18 08:00AM | Altimmune Elects Mitchel Sayare, Ph.D. as Chairman of its Board of Directors GlobeNewswire |
| Dec-28-17 12:45PM | Is Altimmune Incs (NASDAQ:ALT) CEO Paid At A Competitive Rate? Simply Wall St. +8.17% |
| Dec-22-17 11:31AM | ETFs with exposure to Altimmune, Inc. : December 22, 2017 Capital Cube |
| Dec-21-17 04:01PM | Altimmune to Participate in the 10th Annual Biotech Showcase in San Francisco, January 8 10, 2018 GlobeNewswire |
| 08:00AM | Altimmune Announces Positive Initial Data from Its HepTcell Phase 1 Study GlobeNewswire |
| Dec-11-17 01:25PM | ETFs with exposure to Altimmune, Inc. : December 11, 2017 Capital Cube |
| 08:00AM | Altimmune Submits Investigational New Drug Application for NasoShield in Preparation for its Phase 1 Trial GlobeNewswire |
| Nov-30-17 01:15PM | ETFs with exposure to Altimmune, Inc. : November 30, 2017 Capital Cube -6.22% |
| Nov-21-17 08:00AM | Altimmune to Present at the 29th Annual Piper Jaffray Conference GlobeNewswire |
| Nov-20-17 11:31AM | ETFs with exposure to Altimmune, Inc. : November 20, 2017 Capital Cube |
| Nov-17-17 08:34AM | Altimmune, Inc. :ALT-US: Earnings Analysis: Q3, 2017 By the Numbers : November 17, 2017 Capital Cube |
| Nov-09-17 04:01PM | Altimmune Announces Third Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire |
| Nov-02-17 08:00AM | Altimmune to Announce Third Quarter 2017 Financial Results on November 9 GlobeNewswire |
| Oct-25-17 09:48AM | ETFs with exposure to Altimmune, Inc. : October 25, 2017 Capital Cube |
| Oct-10-17 10:58AM | ETFs with exposure to Altimmune, Inc. : October 10, 2017 Capital Cube |
| Sep-22-17 04:56PM | Whats Ahead For Altimmune Inc (ALT)? Simply Wall St. |
| Sep-20-17 08:00AM | Altimmune Announces its Phase 2 Flu Vaccine Trial with NasoVAX Open for Enrollment GlobeNewswire +5.42% |
| Sep-19-17 08:00AM | Altimmune to Provide Corporate Update at the Ladenburg Thalmann 3rd Annual Healthcare Conference GlobeNewswire |
| Sep-06-17 08:00AM | Altimmune to Provide Corporate Update at the Rodman & Renshaw Global Investment Conference GlobeNewswire |
| Aug-25-17 03:44PM | ETFs with exposure to Altimmune, Inc. : August 25, 2017 Capital Cube |
| Aug-23-17 07:11AM | Maryland biotech expanding into new Gaithersburg headquarters American City Business Journals |
| Aug-21-17 04:01PM | Altimmune Closes Series B Preferred Stock Offering GlobeNewswire |
| 08:00AM | Altimmune Submits Investigational New Drug Application for NasoVAX in Preparation for Phase 2 Trial GlobeNewswire |
| Aug-18-17 08:35PM | [$$] Investors Give Altimmune $14.7 Million Boost Following Reverse Merger The Wall Street Journal |
| Aug-17-17 10:09AM | Altimmune, Inc. :ALT-US: Earnings Analysis: Q2, 2017 By the Numbers : August 17, 2017 Capital Cube -5.99% |
| 08:00AM | Altimmune Announces $14.7 Million Series B Preferred Stock Offering GlobeNewswire |
| Aug-10-17 12:25AM | Altimmune Announces Second Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire |
| Jul-31-17 08:00AM | Altimmune to Announce Second Quarter 2017 Financial Results on August 10 GlobeNewswire -6.32% |
| Jul-11-17 02:00PM | ETFs with exposure to Altimmune, Inc. : July 11, 2017 Capital Cube |
| Jun-19-17 08:00AM | Altimmune to Provide Corporate Update at the BIO International Convention GlobeNewswire +12.71% |
| Jun-16-17 03:21PM | ETFs with exposure to Altimmune, Inc. : June 16, 2017 Capital Cube -9.69% |
| May-16-17 08:00AM | Altimmune Promotes Dr. Sybil Tasker to Chief Medical Officer GlobeNewswire -10.81% |
| May-11-17 10:45AM | Altimmune, Inc. :ALT-US: Earnings Analysis: Q1, 2017 By the Numbers : May 11, 2017 Capital Cube |
| May-10-17 10:00AM | Altimmune, Inc. (Nasdaq: ALT) to Ring The Nasdaq Stock Market Opening Bell GlobeNewswire -9.61% |
| May-04-17 04:01PM | Altimmune Completes Merger with PharmAthene Creating Immunotherapeutics Company Targeting Infectious Diseases GlobeNewswire -7.75% |
|
|
|
|
| Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, focuses on discovering and developing immunotherapies and vaccines to address the unmet medical needs. The company develops NasoVAX, an intranasally administered recombinant influenza vaccine that is in Phase II clinical trials; HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials; and NasoShield, a vaccine for the prevention of anthrax disease following inhalation of bacterial spores that is in Phase I clinical trials. Its preclinical stage products include SparVax-L, a recombinant protein-based anthrax vaccine; and Oncosyn, an immunotherapeutic for treating cancer. The company also develops veterinary product candidates. Altimmune, Inc. is headquartered in Gaithersburg, Maryland. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Enright William | President and CEO | May 25 | Buy | 0.51 | 1,300 | 660 | 365,839 | May 29 06:17 PM | | Roberts M Scot | Chief Scientific Officer | May 21 | Option Exercise | 0.08 | 55,120 | 4,410 | 55,120 | May 23 05:23 PM | | Enright William | President and CEO | Jan 02 | Option Exercise | 0.08 | 183,347 | 14,668 | 364,511 | Jan 04 04:53 PM | | SAYARE MITCHEL | Director | Dec 29 | Buy | 1.95 | 5,100 | 9,963 | 32,650 | Jan 03 04:54 PM | | SCHAFFER DERACE L | Director | Dec 29 | Buy | 1.93 | 38,699 | 74,778 | 589,453 | Jan 02 05:09 PM | | SCHAFFER DERACE L | Director | Dec 28 | Buy | 1.92 | 58,711 | 112,672 | 550,754 | Jan 02 05:09 PM | | SCHAFFER DERACE L | Director | Dec 27 | Buy | 1.77 | 77,706 | 137,210 | 492,043 | Dec 27 06:27 PM | | SCHAFFER DERACE L | Director | Dec 26 | Buy | 1.81 | 51,442 | 93,269 | 414,337 | Dec 27 06:27 PM | | SCHAFFER DERACE L | Director | Dec 22 | Buy | 1.61 | 17,982 | 28,877 | 362,895 | Dec 27 06:27 PM | | SCHAFFER DERACE L | Director | Dec 07 | Buy | 1.74 | 7,639 | 13,308 | 344,913 | Dec 08 05:51 PM | | SCHAFFER DERACE L | Director | Dec 06 | Buy | 1.80 | 16,106 | 28,996 | 337,274 | Dec 08 05:51 PM | | SCHAFFER DERACE L | Director | Dec 05 | Buy | 1.78 | 13,495 | 23,987 | 321,168 | Dec 05 05:34 PM | | SCHAFFER DERACE L | Director | Dec 04 | Buy | 1.81 | 7,300 | 13,195 | 307,673 | Dec 05 05:34 PM | | SCHAFFER DERACE L | Director | Dec 01 | Buy | 1.80 | 5,215 | 9,405 | 300,373 | Dec 05 05:34 PM | | SCHAFFER DERACE L | Director | Nov 30 | Buy | 1.84 | 12,978 | 23,816 | 295,158 | Nov 30 05:38 PM | | SCHAFFER DERACE L | Director | Nov 29 | Buy | 1.94 | 7,942 | 15,377 | 282,180 | Nov 30 05:38 PM | | SCHAFFER DERACE L | Director | Nov 28 | Buy | 1.97 | 12,395 | 24,445 | 274,238 | Nov 30 05:38 PM | | SCHAFFER DERACE L | Director | Nov 27 | Buy | 2.00 | 10,042 | 20,060 | 261,843 | Nov 27 05:31 PM | | SCHAFFER DERACE L | Director | Nov 24 | Buy | 2.02 | 6,505 | 13,162 | 251,801 | Nov 27 05:31 PM | | SCHAFFER DERACE L | Director | Nov 22 | Buy | 2.10 | 5,261 | 11,061 | 245,296 | Nov 27 05:31 PM | | SCHAFFER DERACE L | Director | Nov 21 | Buy | 2.06 | 7,236 | 14,905 | 240,035 | Nov 21 06:10 PM | | SCHAFFER DERACE L | Director | Nov 20 | Buy | 2.07 | 4,800 | 9,958 | 232,799 | Nov 21 06:10 PM | | SCHAFFER DERACE L | Director | Nov 17 | Buy | 2.12 | 6,295 | 13,352 | 227,999 | Nov 21 06:10 PM |
|
|
|
|
|
|
